INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer
25 janv. 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting
04 janv. 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium
09 déc. 2021 09h01 HE
|
INmune Bio, Inc.
Data suggests in triple negative breast cancer that MUC4 predicts survival and resistance to immunotherapy and that INB03 reverses resistance by decreasing immunosuppression in the TME Boca...
INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.
01 déc. 2021 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Dec. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update
03 nov. 2021 16h15 HE
|
INmune Bio, Inc.
Announces second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) Cash and cash equivalents of $84.5 million...
INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting
27 oct. 2021 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3
25 oct. 2021 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Oct. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s...
INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series
27 sept. 2021 16h00 HE
|
INmune Bio, Inc.
Boca Raton, FL, Sept. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences
20 sept. 2021 16h00 HE
|
INmune Bio, Inc.
BOCA RATON, Florida, Sept. 20, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination
01 sept. 2021 16h00 HE
|
INmune Bio, Inc.
Company to present additional phase 1b data during webinar on Sept 7th, 2021 at 4:30 pm EST. Boca Raton, FL, Sept. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a...